A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with Type 2 diabetes

P D Home, C J Bailey, J Donaldson, H Chen, M W Stewart, P D Home, C J Bailey, J Donaldson, H Chen, M W Stewart

Abstract

Aims: To compare the efficacy and safety of either continuing or discontinuing rosiglitazone + metformin fixed-dose combination when starting insulin therapy in people with Type 2 diabetes inadequately controlled on oral therapy.

Methods: In this 24-week double-blind study, 324 individuals with Type 2 diabetes inadequately controlled on maximum dose rosiglitazone + metformin therapy were randomly assigned to twice-daily premix insulin therapy (target pre-breakfast and pre-evening meal glucose < or = 6.5 mmol/l) in addition to either rosiglitazone + metformin (8/2000 mg) or placebo.

Results: Insulin dose at week 24 was significantly lower with rosiglitazone + metformin (33.5 +/- 1.5 U/day, mean +/- se) compared with placebo [59.0 +/- 3.0 U/day; model-adjusted difference -26.6 (95% CI -37.7, -15,5) U/day, P < 0.001]. Despite this, there was greater improvement in glycaemic control [HbA(1c) rosiglitazone + metformin vs. placebo 6.8 +/- 0.1 vs. 7.5 +/- 0.1%; difference -0.7 (-0.8, -0.5)%, P < 0.001] and more individuals achieved glycaemic targets (HbA(1c) < 7.0% 70 vs. 34%, P < 0.001). The proportion of individuals reporting at least one hypoglycaemic event during the last 12 weeks of treatment was similar in the two groups (rosiglitazone + metformin vs. placebo 25 vs. 27%). People receiving rosiglitazone + metformin in addition to insulin reported greater treatment satisfaction than those receiving insulin alone. Both treatment regimens were well tolerated but more participants had oedema [12 (7%) vs. 4 (3%)] and there was more weight gain [3.7 vs. 2.6 kg; difference 1.1 (0.2, 2.1) kg, P = 0.02] with rosiglitazone + metformin.

Conclusions: Addition of insulin to rosiglitazone + metformin enabled more people to reach glycaemic targets with less insulin, and was generally well tolerated.

Figures

FIGURE 1
FIGURE 1
Time courses for daily insulin dose, HbA1c and clinic FPG for people with Type 2 diabetes starting insulin while continuing rosiglitazone + metformin (□) or transferring to placebo (•). Data are mean ± se for ITT populations with LOCF, except for dose which is without LOCF. For statistical significance see Results and Table 2.

References

    1. Klein R. The medical management of hyperglycemia over a 10-year period in people with diabetes. Diabetes Care. 1996;19:744–750.
    1. Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care. 2001;24:758–767.
    1. Goudswaard AN. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2004. CD003418.
    1. Yki-Järvinen H. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1999;130:389–396.
    1. Chow CC. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care. 1995;18:307–314.
    1. Douek IF. Continuing metformin when starting insulin in patients with Type 2 diabetes: a double-blind randomized placebo-controlled trial. Diabet Med. 2005;22:634–640.
    1. Canadian Diabetes Association. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2003. pp. S1–S152.
    1. International Diabetes Federation Clinical Guidelines Taskforce. Global Guideline for Type 2 Diabetes. [2006-September-4]. Available from: .
    1. Einhorn D. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther. 2000;22:1395–1409.
    1. Fonseca V. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. J Am Med Assoc. 2000;283:1695–1702.
    1. Jones TA. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab. 2003;5:163–170.
    1. Bailey CJ, et al. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes: a 24-week, randomized, double-blind, parallel-group study. Clin Ther. 2005;27:1548–1561.
    1. Bailey CJ. Avandamet: combined metformin–rosiglitazone treatment for insulin resistance in type 2 diabetes. Int J Clin Pract. 2004;58:867–876.
    1. Miyazaki Y, et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia. 2001;44:2210–2219.
    1. Stumvoll M. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:550–554.
    1. Bailey CJ. Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes Metab. 2005;7:675–691.
    1. Garber AJ. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose–response trial. Am J Med. 1997;103:491–497.
    1. Rosak C. Rosiglitazone plus metformin is effective and well tolerated in clinical practice: results from large observational studies in people with type 2 diabetes. Int J Clin Pract. 2005;59:1131–1136.
    1. Raskin P. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care. 2001;24:1226–1232.
    1. Nesto RW, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004;27:256–263.
    1. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its ComplicationsPart IDiagnosis and Classification of Diabetes Mellitus. Geneva: WHO Department of Noncommunicable Disease Surveillance; 1999.
    1. Bradley C. Diabetes Treatment Satisfaction Questionnaire (DTSQ) In: Bradley C, editor. Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Management. Langhorne: Harwood Academic Publishers; 1994.
    1. Rosenstock J. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care. 2004;27:1318–1323.
    1. UK Prospective Diabetes Study (UKPDS) Group. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med. 1998;128:165–175.
    1. Despres JP, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334:952–957.
    1. Riddle MC. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080–3086.
    1. Yki-Järvinen H. Treat To Target simply—the LANMET study. Diabetes. 2004;53(Suppl. 2):A519.
    1. Raskin P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260–265.
    1. European Diabetes Policy Group. A desktop guide to Type 2 diabetes. Diabet Med. 1999;16:716–730.
    1. Lebovitz HE, et al. ACE/AACE consensus conference on the implementation of out patient management of diabetes mellitus: consensus conference reccommendations. Endocr Pract. 2006;12(Suppl. 1):6–12.
    1. Janka HU. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005;28:254–259.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner